Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration

Molecular Psychiatry

Volumn 21, Issue 3, 2016, Pages 328-338

  Ferres Coy A ^a,b,c   Galofre M ^a,b,c   Pilar Cuellar F ^c,d   Vidal, R ^c,d   Paz, V ^a,b,c   Ruiz Bronchal, E ^a,b,c   Campa, L ^a,b,c   Pazos, A ^c,d   Caso, J R ^c,e   Leza, J C ^c,e   Alvarado, G ^f   Montefeltro, A ^f   Valdizan E M ^c,d   Artigas, F ^a,b,c   Bortolozzi, A ^a,b,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INST D INVESTIGACIONS B   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d University of Cantabria   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f n Life TherapeuticsSL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; AUTORECEPTOR; FLUOXETINE; OLIGONUCLEOTIDE; SEROTONIN; SEROTONIN TRANSPORTER; SERTRALINE; SMALL INTERFERING RNA; ARABIDOPSIS PROTEIN; COMPLEMENTARY DNA; CORTICOSTERONE; ENOLASE; MARNERAL SYNTHASE, ARABIDOPSIS; MUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CELL BODY; CELL PROLIFERATION; CONTROLLED STUDY; FOREBRAIN; MALE; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; OLFACTORY EPITHELIUM; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; ANIMAL; BLOOD; C57BL MOUSE; CYTOLOGY; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; ENDOCYTOSIS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; TIME FACTOR;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIDEPRESSIVE AGENTS; ARABIDOPSIS PROTEINS; BRAIN; CORTICOSTERONE; DEPRESSION; DISEASE MODELS, ANIMAL; DNA, ANTISENSE; ENDOCYTOSIS; EXPLORATORY BEHAVIOR; FLUOXETINE; GENE EXPRESSION REGULATION; INTRAMOLECULAR TRANSFERASES; MALE; MICE; MICE, INBRED C57BL; NEURONS; PHOSPHOPYRUVATE HYDRATASE; RNA, SMALL INTERFERING; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SERTRALINE; TIME FACTORS;

EID: 84958833745     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.80     Document Type: Article

References (48)

1. Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001; 2: 343-351.
2. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68.
3. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
4. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatry Res 2003; 37: 357-373.
5. Blakely RD, De Felice LJ, Hartzell HC. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 1994; 196: 263-281.
6. Quin Y, Melikian HE, Rye DB, Levey AI, Blakely RD. Identification and characterization of antidepressant-sensitive serotonin transporter proteins using sitespecific antibodies. J Neurosci 1995; 15: 1261-1274.
7. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry 2006; 163: 1905-1917.
8. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252.
9. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG., et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999; 19: 10494-10501.
10. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 2002; 22: 6766-6772.
11. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Weisstaub N., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809.
12. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I., et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009; 62: 479-493.
13. Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S. A role for p38 mitogenactivated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci 2005; 25: 29-41.
14. Lau T, Horschitz S, Berger S, Bartsch D, Schloss P. Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons. FASEB J 2008; 22: 1702-1714.
15. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010; 329: 1537-1541.
16. Thakker DR, Natt F, Hüsken D, van der Putten H, Maier R, Hoyer D., et al. siRNAmediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry 2005; 10: 782-789.
17. Ferrés-Coy A, Pilar-Cuéllar F, Vidal R, Paz V, Masana M, Cortés R., et al. RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis. Transl Psychiatry 2013; 15: e211.
18. Bortolozzi A, Castañé A, Semakova J, Santana N, Alvarado G, Cortés R., et al. Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. Mol Psychiatry 2012; 17: 612-623.
19. Fabre V, Boutrel B, Hanoun N, Lanfumey L, Fattaccini CM, Demeneix B., et al. Homeostatic regulation of serotonergic function by the serotonin transporter as revealed by nonviral gene transfer. J Neurosci 2000; 20: 5065-5075.
20. Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 2009; 6: 686-695.
21. Boudreau RL, Rodríguez-Lebrón E, Davidson BL. RNAi medicine for the brain: progresses and challenges. Hum Mol Genet 2011; 20: 21-27.
22. Gourley SL, Taylor JR. Recapitulation and reversal of a persistent depression-like syndrome in rodents. Curr Protoc Neurosci 2009; Chapter 9: Unit 9.32.
23. Gourley SL, Kiraly DD, Howell JL, Olausson P, Taylor JR. Acute hippocampal brainderived neurotrophic factor restores motivational and forced swim performance after corticosterone. Biol Psychiatry 2008; 64: 884-890.
24. Pérez-Nievas BG, García-Bueno B, Caso JR, Menchén L, Leza JC. Corticosterone as a marker of susceptibility to oxidative/nitrosative cerebral damage after stress exposure in rats. Psychoneuroendocrinol 2007; 32: 703-711.
25. Ferrés-Coy A, Santana N, Castañé A, Cortés R, Carmona MC., et al. Acute 5-HT1A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. Psychopharmacology (Berl) 2013; 225: 61-74.
26. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. Academic Press: New York, NY, USA, 2008.
27. Samuels BA, Hen R. Novelty-suppressed feeding in the mouse. In: Gould TD (ed). Mood and Anxiety Related Phenotypes in Mice: Characterization Using Behavioral Tests, Volume II. Springer: New York, NY, USA, 2011; pp 107-121.
28. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003; 4: 13-25.
29. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378-383.
30. Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594-1597.
31. Artigas F, Celada P, Laruelle M, Adell A. How does pindolol improve antidepressant action?. Trends Pharmacol Sci 2001; 22: 224-228.
32. Hensler JG. Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 2002; 26: 565-573.
33. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012; 338: 68-72.
34. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-Acting agents. Trends Neurosci 2012; 35: 47-56.
35. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS. PSD-95 involvement in maturation of excitatory synapses. Science 2000; 290: 1364-1368.
36. Hu X, Ballo L, Pietila L, Viesselmann C, Ballweg J, Lumbard D., et al. BDNF-induced increase of PSD-95 in dendritic spines requires dynamic microtubule invasions. J Neurosci 2011; 31: 15597-15603.
37. Son H, Banasr M, Choi M, Chae SY, Licznerski P, Lee B., et al. Neuritin produces antidepressant actions and blocks the neuronal and behavioral deficits caused by chronic stress. Proc Natl Acad Sci USA 2012; 109: 11378-11383.
38. Ming X, Rowshon Alan Md, Fisher M, Yan Y, Chen X, Juliano RL., et al. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res 2010; 38: 6567-6576.
39. Juliano RL, Carver K, Cao C, Ming X. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J Drug Targeting 2013; 21: 27-43.
40. Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010; 99: 1654-1673.
41. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012; 64: 614-628.
42. Renner DB, Frey WH 2nd, Hanson LR. Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. Neurosci Lett 2012; 513: 193-197.
43. Mamounas LA, Mullen CA, O'hearn E, Molliver ME. Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 1999; 314: 558-586.
44. Brown P, Molliver ME. Dual serotonin (5-HT) projections to the nucleus accumbens core and shell: relation of the 5-HT transporter to amphetamine-induced neurotoxicity. J Neurosci 2000; 20: 1952-1963.
45. Hervás I, Queiroz CMT, Adell A, Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br J Pharmacol 2000; 130: 160-166.
46. Lopez JP, Lim R, Cruceanu C, Crapper L, Fasano C, Labonte B., et al. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med 2014; 20: 764-768.
47. Issler O, Haramati S, Paul ED, Maeno H, Navon I, Zwang R., et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 2014; 83: 344-360.
48. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 2008; 28: 1374-1384.